UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for Long COVID in the United Kingdom. Explore treatment pathways for post-COVID syndrome including fatigue, brain fog, and cardiovascular complications.
Long COVID (post-COVID-19 condition) affects an estimated 2 million people in the UK. Symptoms persist for more than 12 weeks after initial COVID-19 infection and can include debilitating fatigue, brain fog, breathlessness, chest pain, palpitations, joint pain, and mood changes. The condition can affect anyone regardless of initial COVID severity, and there is no proven pharmaceutical treatment yet.
NHS Long COVID services offer rehabilitation programmes, physiotherapy, occupational therapy, and psychological support. There are currently no approved medications specifically for Long COVID. Management focuses on symptom control, pacing strategies, and graded exercise therapy where appropriate. Many patients are turning to clinical trials for access to potential treatments.
The UK is leading global Long COVID research through the NIHR and dedicated research programmes. Key areas: antiviral treatments (nirmatrelvir, metformin), anti-inflammatory approaches, microclot and endothelial dysfunction therapies, autonomic nervous system treatments, gut microbiome interventions, and rehabilitation approaches. The HEAL-COVID and TLC trials are major UK studies.
UK Long COVID trials are recruiting across NHS hospitals. Trials range from drug interventions (antivirals, anti-inflammatories, antihistamines) to device-based therapies and rehabilitation approaches. Many trials accept participants regardless of vaccination status. The NHS Your Covid Recovery platform provides information about available studies.
Free AI-powered matching - no signup required
Search post-COVID syndrome Trials →